US infant formula firm Abbott Laboratories has reported flat half-year sales from its nutrition division, which houses its baby and adult nutrition businesses.
Abbott said its sales, excluding the impact of foreign currency, inched up 0.7% in the first six months of the year. On a reported basis, including foreign exchange, sales were down 1.2% at US$3.36bn.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company said its pediatric nutrition sales increased 1.1% in the second quarter when currency fluctuations were excluded from the results and fell 0.5% with the foreign exchange impact included.
Abbott said the disruption to its sales last August after supplier Fonterra recalled a batch of whey protein concentrate amid a botulism scare impacted the year-over-year sales comparison in its international pediatric nutrition business by $40m.
Abbott said it is “recapturing share” in the affected markets. It launched several products during the quarter and opened a new nutrition manufacturing plant in China, which will manufacture its Similac Qinti infant formula.
Worldwide adult nutrition sales increased 5.7% during the second quarter when the impact of foreign exchange was removed from the results. Including currency fluctuations, sales were up 4.4%.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
